OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Protection of the kidney with sodium–glucose cotransporter 2 inhibitors: potential mechanisms raised by the large-scaled randomized control trials
Satoru Kuriyama
Clinical and Experimental Nephrology (2018) Vol. 23, Iss. 3, pp. 304-312
Closed Access | Times Cited: 17
Satoru Kuriyama
Clinical and Experimental Nephrology (2018) Vol. 23, Iss. 3, pp. 304-312
Closed Access | Times Cited: 17
Showing 17 citing articles:
Sodium Glucose Cotransporter-2 Inhibition and Cardiorenal Protection
David Z.I. Cherney, Ayodele Odutayo, Ronnie Aronson, et al.
Journal of the American College of Cardiology (2019) Vol. 74, Iss. 20, pp. 2511-2524
Open Access | Times Cited: 65
David Z.I. Cherney, Ayodele Odutayo, Ronnie Aronson, et al.
Journal of the American College of Cardiology (2019) Vol. 74, Iss. 20, pp. 2511-2524
Open Access | Times Cited: 65
SGLT2 inhibitors: a narrative review of efficacy and safety
Donald S. Nelinson, José Manuel Sosa, Robert Ćhilton
Journal of Osteopathic Medicine (2021) Vol. 121, Iss. 2, pp. 229-239
Open Access | Times Cited: 41
Donald S. Nelinson, José Manuel Sosa, Robert Ćhilton
Journal of Osteopathic Medicine (2021) Vol. 121, Iss. 2, pp. 229-239
Open Access | Times Cited: 41
Canagliflozin potentially promotes renal protection against glycerol-induced acute kidney injury by activating the AMPK/SIRT1/FOXO-3a/PGC-1α and Nrf2/HO-1 pathways
Abeer Bishr, Ahmed M. Atwa, Bassant M El-Mokadem, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Open Access
Abeer Bishr, Ahmed M. Atwa, Bassant M El-Mokadem, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Open Access
A new strategy for vascular complications in young people with type 1 diabetes mellitus
M. Loredana Marcovecchio, R. Neil Dalton, Denis Daneman, et al.
Nature Reviews Endocrinology (2019) Vol. 15, Iss. 7, pp. 429-435
Open Access | Times Cited: 27
M. Loredana Marcovecchio, R. Neil Dalton, Denis Daneman, et al.
Nature Reviews Endocrinology (2019) Vol. 15, Iss. 7, pp. 429-435
Open Access | Times Cited: 27
Small dense low-density lipoprotein-lowering agents
Shahin Alizadeh‐Fanalou, Ali Nazarizadeh, Fatemeh Alian, et al.
Biological Chemistry (2020) Vol. 401, Iss. 10, pp. 1101-1121
Closed Access | Times Cited: 21
Shahin Alizadeh‐Fanalou, Ali Nazarizadeh, Fatemeh Alian, et al.
Biological Chemistry (2020) Vol. 401, Iss. 10, pp. 1101-1121
Closed Access | Times Cited: 21
SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients
В. В. Салухов, Yurii Sh. Khalimov, С Б Шустов, et al.
Diabetes Mellitus (2021) Vol. 23, Iss. 5, pp. 475-491
Open Access | Times Cited: 12
В. В. Салухов, Yurii Sh. Khalimov, С Б Шустов, et al.
Diabetes Mellitus (2021) Vol. 23, Iss. 5, pp. 475-491
Open Access | Times Cited: 12
Renal function dynamics following co‐administration of sacubitril/valsartan and empagliflozin in patients with heart failure and type 2 diabetes
Rafael de la Espriella, Antoni Bayés‐Genís, Herminio Morillas, et al.
ESC Heart Failure (2020) Vol. 7, Iss. 6, pp. 3792-3800
Open Access | Times Cited: 11
Rafael de la Espriella, Antoni Bayés‐Genís, Herminio Morillas, et al.
ESC Heart Failure (2020) Vol. 7, Iss. 6, pp. 3792-3800
Open Access | Times Cited: 11
Advantages of therapy with sodium glucose cotransporter type 2 inhibitors in patients with type 2 diabetes mellitus in combination with hyperuricemia and gout
Т. С. Паневин, М. С. Елисеев, М. В. Шестакова, et al.
Terapevticheskii arkhiv (2020) Vol. 92, Iss. 5, pp. 110-118
Open Access | Times Cited: 10
Т. С. Паневин, М. С. Елисеев, М. В. Шестакова, et al.
Terapevticheskii arkhiv (2020) Vol. 92, Iss. 5, pp. 110-118
Open Access | Times Cited: 10
Canagliflozin Promotes Mitochondrial Biogenesis in Glycerol-Induced Acute Kidney Injury by Activating the AMPK/SIRT1/FOXO-3a/ PGC-1α and Nrf2/HO-1 Trajectories
Abeer Bishr, Ahmed M. Atwa, Mostafa E. El-Naggar, et al.
SSRN Electronic Journal (2021)
Closed Access | Times Cited: 2
Abeer Bishr, Ahmed M. Atwa, Mostafa E. El-Naggar, et al.
SSRN Electronic Journal (2021)
Closed Access | Times Cited: 2
Is cancer incidence modified by SGLT2 inhibitors?
Lev M. Berstein
Diabetes Mellitus (2019) Vol. 22, Iss. 4, pp. 399-402
Open Access | Times Cited: 1
Lev M. Berstein
Diabetes Mellitus (2019) Vol. 22, Iss. 4, pp. 399-402
Open Access | Times Cited: 1
SGLT2-Inhibitoren bei diabetischer Nephropathie
Eva Dumann, Hermann Haller, Jan Menne
Der Nephrologe (2020) Vol. 15, Iss. 3, pp. 153-162
Closed Access | Times Cited: 1
Eva Dumann, Hermann Haller, Jan Menne
Der Nephrologe (2020) Vol. 15, Iss. 3, pp. 153-162
Closed Access | Times Cited: 1
Correction of the prooxidant-antioxidant balance disorders in patients with diabetic kidney disease
А. О. Nesen, P. S. Semenovykh, V. Galchiskaya, et al.
Ukrainian Journal of Nephrology and Dialysis (2023), Iss. 3(79), pp. 45-53
Open Access
А. О. Nesen, P. S. Semenovykh, V. Galchiskaya, et al.
Ukrainian Journal of Nephrology and Dialysis (2023), Iss. 3(79), pp. 45-53
Open Access
Les inhibiteurs des SGLT2 : traitement anti diabétiques et/ou de la prévention cardiovasculaire et/ou protection rénale ? Place au débat
Michel Krempf
Archives of Cardiovascular Diseases Supplements (2019) Vol. 11, pp. S23-S29
Open Access
Michel Krempf
Archives of Cardiovascular Diseases Supplements (2019) Vol. 11, pp. S23-S29
Open Access
Mechanisms of GLP‒1 Receptor Agonists on the Cardio-Renal Protective Effects
Satoru Kuriyama, Kei Matsumoto
Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics (2022) Vol. 53, Iss. 6, pp. 249-262
Closed Access
Satoru Kuriyama, Kei Matsumoto
Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics (2022) Vol. 53, Iss. 6, pp. 249-262
Closed Access
SGLT2 阻害薬はなぜ非糖尿病患者においても心・腎保護的か？
Satoru Kuriyama, Kei Matsumoto, Maki Hirao, et al.
Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics (2021) Vol. 52, Iss. 6, pp. 157-164
Closed Access
Satoru Kuriyama, Kei Matsumoto, Maki Hirao, et al.
Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics (2021) Vol. 52, Iss. 6, pp. 157-164
Closed Access
